首页> 外文期刊>Medical principles and practice: international journal of the Kuwait University, Health Science Centre >The Value of Transvaginal Ultrasonography in the Endometrial Evaluation of Breast Cancer Patients Using Tamoxifen
【24h】

The Value of Transvaginal Ultrasonography in the Endometrial Evaluation of Breast Cancer Patients Using Tamoxifen

机译:经阴道超声检查在使用他莫昔芬治疗乳腺癌患者子宫内膜评估中的价值

获取原文
           

摘要

AbstractObjective: To estimate the value of transvaginal ultrasonography (TVU) in evaluating the endometrium in breast cancer patients on tamoxifen, and to investigate the relationship between TVU and histologic endometrial findings in these patients. Subjects and Methods: 107 breast cancer patients taking tamoxifen were included in this study. TVU was performed twice for each patient: prior to starting tamoxifen therapy and 1 year after taking tamoxifen. An endometrial thickness of ≥5 mm was considered abnormal. Endometrial biopsy was performed at the same time the 2nd TVU was done. The patients were divided into 2 groups: symptomatic (group A) and asymptomatic (group B), based on whether or not there was abnormal vaginal bleeding. Results: 31 patients (29%) were symptomatic, while the remaining 76 (71%) were asymptomatic. The endometrial thickness increased after 1 year of taking tamoxifen from 4.84 ± 0.4 mm to 6.34 ± 2.1 mm in group A and from 4.73 ± 0.3 mm to 5.67 ± 1.95 mm in group B (p 0.05). Endometrial biopsy revealed 77 (71.96%) atrophic endometria and 21 (19.62%) polyps. A comparison between the 2 groups showed a significant difference in patients with endometrial atrophy and atypical hyperplasia. Patients who had an endometrial thickness of 5 mm had a significantly higher prevalence of atypical hyperplasia (p = 0.003) and polyps (p = 0.041). The sensitivity, specificity, positive predictive and negative predictive values of TVU were 63.3, 28.57, 25.67 and 66.66%, respectively. Conclusion: Our study showed a discrepancy between TVU and endometrial biopsy findings, due to the specific histology of the endometrium in breast cancer patients using tamoxifen. Due to this discrepancy, TVU alone is not an effective screening test for endometrial pathology and its application alone might lead to an undesirably high frequency of invasive diagnostic procedures.Copyright © 2010 S. Karger AG, Basel.
机译:摘要目的:评估经阴道超声检查在他莫昔芬治疗乳腺癌患者子宫内膜中的价值,并探讨TVU与这些患者的组织学子宫内膜发现之间的关系。对象和方法:107例服用他莫昔芬的乳腺癌患者被纳入本研究。每个患者接受两次TVU:开始他莫昔芬治疗前和服用他莫昔芬1年后。子宫内膜厚度≥5mm被认为是异常的。进行第二次TVU的同时进行子宫内膜活检。根据是否有异常阴道出血将患者分为两组:有症状的(A组)和无症状的(B组)。结果:31例(29%)有症状,而其余76例(71%)无症状。服用他莫昔芬1年后,子宫内膜厚度从A组的4.84±0.4 mm增加到6.34±2.1 mm,B组从4.73±0.3 mm增加到5.67±1.95 mm(p> 0.05)。子宫内膜活检显示有77(71.96%)萎缩性子宫内膜和21(19.62%)息肉。两组之间的比较显示,子宫内膜萎缩和非典型增生患者之间存在显着差异。子宫内膜厚度> 5 mm的患者非典型增生(p = 0.003)和息肉(p = 0.041)的患病率明显更高。 TVU的敏感性,特异性,阳性预测值和阴性预测值分别为63.3、28.57、25.67和66.66%。结论:我们的研究表明,由于使用他莫昔芬的乳腺癌患者子宫内膜的特殊组织学,TVU与子宫内膜活检结果之间存在差异。由于这种差异,仅TVU并不是对子宫内膜病理的有效筛查测试,仅TVU的应用可能会导致侵入性诊断程序出现不希望的高频率。版权所有©2010 S. Karger AG,巴塞尔。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号